Paclitaxel and Epirubicin for Advanced Breast Cancer
Author Information
Author(s): Rischin D, Smith J, Millward M, Lewis C, Boyer M, Richardson G, Toner G, Gurney H, McKendrick J
Primary Institution: Peter MacCallum Cancer Institute, Melbourne
Hypothesis
The study investigates the efficacy and safety of paclitaxel combined with epirubicin in patients with advanced breast cancer.
Conclusion
Paclitaxel and epirubicin is a well-tolerated and promising treatment for advanced breast cancer.
Supporting Evidence
- The response rate was 54%, with 12% complete responses and 42% partial responses.
- Estimated median progression-free survival was 6.9 months.
- Estimated median overall survival was 17.9 months.
- Grade 4 neutropenia occurred in 56% of cycles.
Takeaway
Doctors tested a new medicine for breast cancer and found it works well without causing too many side effects.
Methodology
Patients with advanced breast cancer were treated with epirubicin followed by paclitaxel every 3 weeks.
Limitations
The study had a small sample size and limited follow-up.
Participant Demographics
Patients had performance status 0–2 and measurable disease.
Statistical Information
Confidence Interval
95% CI 38–69%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website